Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c
Authors' conclusion
Despite compelling indications, initiation of SGLT2i and GLP-1RA remained low overall and was significantly lower among Black and Hispanic patients, underscoring therapeutic inertia as a modifiable barrier to optimal diabetes care.
Study context
- Population
- Patients with T2D and above-target HbA1c with clinical indications for SGLT2i or GLP-1 RA, not currently using them, no contraindications; 56% White, 37% Black, 3% Hispanic, 2% Asian, 2% other
- Participants
- 10,345 patients30,740 encounters
- Exposure
- New SGLT2i or GLP-1 RA prescribing by race and ethnicity
- Outcome
- Therapeutic inertia: lack of new prescription orders for SGLT2i or GLP-1 RA
Methodological detailselectronic health record data 2018-2022, log-link Poisson generalized estimating equation models
- Electronic health record data 2018-2022
- Log-link Poisson generalized estimating equation models
Main finding
As reported in the abstract
New prescribing rate · 2018-2022
New SGLT2i prescribing increased over time but remained low
0.9%-4.3%
New GLP-1 RA prescribing increased over time but remained low
1.2%-5.2%
Observational data: associations, not effects.
Further findings
| Outcome | RR (95% CI) | |
|---|---|---|
| New SGLT2i prescription by race and ethnicityBlackvs WhiteAdjusted for sociodemographic, clinical and service factors | 0.59 (0.42–0.82) | |
| New GLP-1 RA prescription by race and ethnicityBlackvs WhiteAdjusted for sociodemographic, clinical and service factors | 0.62 (0.49–0.79) | |
| New GLP-1 RA prescription by race and ethnicityHispanicvs WhiteAdjusted | 0.48 (0.25–0.92) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c. BMJ Open Diabetes Res Care. Published 22 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →